ISEE · IVERIC bio
Acquired Company
Astellas completed the acquisition of IVERIC bio, Inc. on July 11, 2023.
IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.
1 Penn Plz Fl 35, New York, 10119-0002, US
Pharmaceutical Preparation Manufacturing
Manufacturing
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$39.95
Open
$39.95
Volume
N/A
Day Range
$39.95 - $39.95
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
0.66%
Institutional Own.
N/A
Qtr Updated
Mar 31st 2024